That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week for four weeks. However, it has a broader label as ...
Spravato has been approved since 2019 for TRD, with its label extended the following year ... further evidence for the use of esketamine nasal spray in this difficult-to-treat population and ...
“There were calls that went well late into the night, and that’s okay, that’s how good opportunities emerge,” George Mathew, managing director at Insight Partners, described with a gri ...
It was easy for them to apply thanks to the propellant used in spray-on sunscreens. They had no way of knowing the gas, derived from fossil fuel, wasn’t properly purified and contaminated the ...